Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7832195 | 0.81 | MAPT (0.47) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL12148577 | 0.78 | GAA (0.50) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL145904 | 0.77 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL8991932 | 0.76 | MEN1 (0.40) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7864240 | 0.75 | MAPT (0.47) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3419077 | 0.74 | GAA (0.47) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3294487 | 0.73 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL9769951 | 0.73 | CHRM2 (0.40) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL11181047 | 0.73 | MEN1 (0.43) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL9178083 | 0.73 | MEN1 (0.43) | MAPTMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-3055313-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
| US-8012958-B2 | Modulate gene expression of gamma-aminobutyric acid receptors ; antidepressants; psychological disorders; obsessive compulsive disorders ; eating disorders | Hythlam, Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080280885-A1 | Methods for Treating Anxiety Related Disorders | HYTHIAM, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080255097-A1 | Methods for the Treatment of Substance Abuse and Dependence | HYTHIAM, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-4382983-A | PARTIALLY HYDROLYZED SILOXANE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | MAPT 4390/4885MEN1 3162/4885KMT2A 2559/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | MAPT 4390/4885MEN1 3162/4885KMT2A 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.